Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.

You may also be interested in...



Evotec Drug Development Strategy Offers Little Downside, Big Upside

Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.

Evotec Buys Bionamics For Shortcut To German Academic Gems

In a novel move to overcome the slowdown in outsourcing, small-molecule drug discovery company Evotec has bought asset manager Bionamics to more quickly progress assets originating in German academia.

Third Quarter Earnings Briefs: Lilly, Bristol, Shire, Biomarin, Alexion

Lilly lowers expectations for Cymbalta; Celgene’s Abraxane continues with strong sales; Bristol touts the potential of Eliquis and Bydureon, despite slow sales; Ornskov discusses One Shire plan; BioMarin readies fifth compound for the clinic, and more.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel